Can Hepatitis B Be A Blockbuster Bug?

By | July 1, 2015

Scalper1 News

The new class of hepatitis C drugs, led by Gilead Sciences (GILD) and AbbVie (ABBV), has turned into one of the biggest success stories in biotech history. Yet hepatitis C is one of only five viruses that cause viral hepatitis. Do any of the others have such lucrative potential? One possibility is hepatitis B, which despite the existence of a vaccine infects even more people than hep C. The World Health Organization estimates that about 240 Scalper1 News

Scalper1 News